RxSight (RXST) Q2 2026 Earnings Call Transcript
RxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.
How this was made
The 30-second read
Why it matters
The key tradable change is the company’s decision to withdraw full-year 2026 guidance while it completes an assessment, increasing uncertainty around revenue and margin trajectory. Q2 results show weaker product sales and LAL unit volumes, partially offset by Alcon collaboration revenue recognized in the quarter.
Market read
Traders should reprice RXST around higher uncertainty for 2026 due to guidance withdrawal, while monitoring the variable timing of Alcon-related revenue recognition.
What to watch
Gross margin commentary is internally mixed (71.2% excluding collaboration vs 76.7% reported), and the installed base of 1,166 LDD units could support future conversion despite near-term trialing headwinds.
Background
RxSight’s adjustable LAL platform is positioned as differentiated in cataract surgery, with a strategic collaboration with Alcon providing upfront and milestone economics.
Ticker impact
RxSight reported Q2 revenue of $33.7M, product sales down 19% YoY, and withdrew full-year 2026 guidance while resuming guidance in early 2027.
Likely choppy trading with downside risk from the guidance withdrawal, partially tempered by the $200M upfront and ongoing Alcon milestone/royalty structure.
The article contains concrete Q2 financials, a clear decision to withdraw full-year guidance, and directional commentary on variable Alcon revenue timing, which typically increases uncertainty and volatility.
Market effects
Signals heightened competitive pressure in LAL adoption and inventory flow-through dynamics for cataract-technology suppliers.
No specific regional demand signal beyond general marketplace headwinds.
Alcon collaboration provides broader validation, but variable milestone timing limits near-term cross-sector read-through.
Counterpoint
The guidance withdrawal may be conservative rather than deteriorating fundamentals, since Alcon-related revenue is still expected at $30M to $40M for 2026.
Key entities
- companyRxSight
Adjustable LAL cataract technology company reporting Q2 2026 results and withdrawing full-year guidance.
- companyAlcon
Strategic collaboration partner providing upfront and milestone payments and collaboration revenue recognized in Q2.
- personRon Kurtz
Continuing as Chief Medical Officer, with clinical and product expertise tied to the adjustable IOL platform.
- personAziz
Speaker on the call discussing platform differentiation, clinical evidence, and the guidance withdrawal decision.
- personMark Wilterding
Speaker reviewing Q2 financial results and directional commentary for the remainder of 2026.
